Supplemental Table 1 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer

Demographics of the METex14-mutated and EGFR-mutated cohorts.